A 13-year-old boy with a history of asthma and seasonal allergies is currently using albuterol to manage his asthma symptoms. Recently, his use of albuterol increased from 1–2 days/week to 4 times/week over the past several weeks, though he does not experience his symptoms daily. The vital signs include: temperature 36.7°C (98.0°F), blood pressure 126/74 mm Hg, heart rate 74/min, and respiratory rate 14/min. His physical examination shows clear, bilateral breath sounds and normal heart sounds. What change should be made to his current treatment regimen?
Q482
A 25-year-old woman is brought to the emergency department 12 hours after ingesting 30 tablets of an unknown drug in a suicide attempt. The tablets belonged to her father, who has a chronic heart condition. She has had nausea and vomiting. She also reports blurring and yellowing of her vision. Her temperature is 36.7°C (98°F), pulse is 51/min, and blood pressure is 108/71 mm Hg. Abdominal examination shows diffuse tenderness with no guarding or rebound. Bowel sounds are normal. An ECG shows prolonged PR-intervals and flattened T-waves. Further evaluation is most likely to show which of the following electrolyte abnormalities?
Q483
A 52-year-old woman complains of severe vomiting for the past 2 hours. She recently had a chemotherapy session for breast cancer. She denies a history of any relevant gastrointestinal diseases, including GERD. The physical exam does not demonstrate any epigastric or abdominal tenderness. The last bowel movement was yesterday and was normal. What is the primary mechanism of the drug which would be prescribed to treat her chief complaint?
Q484
A 55-year-old male is hospitalized for acute heart failure. The patient has a 20-year history of alcoholism and was diagnosed with diabetes mellitus type 2 (DM2) 5 years ago. Physical examination reveals ascites and engorged paraumbilical veins as well as 3+ pitting edema around both ankles. Liver function tests show elevations in gamma glutamyl transferase and aspartate transaminase (AST). Of the following medication, which most likely contributed to this patient's presentation?
Q485
A patient with Graves' disease is treated with thiocyanate (a historical antithyroid agent). Thiocyanate helps reduce thyroid hormone production by:
Q486
A 42-year-old woman, gravida 1, para 0, at 10 weeks' gestation comes to the physician for a prenatal examination. She has no history of significant medical illness. Physical examination shows a uterus consistent with a 10-week gestation. Cell-free fetal DNA testing shows a karyotype of 47,XXY. If the fetus's condition had not been diagnosed until puberty, which of the following sets of hormonal changes would most likely be found at that time?
$$$ Follicle-stimulating hormone %%% Luteinizing hormone %%% Testosterone %%% Estrogen $$$
Q487
A 30-year-old woman with a 1-year history of medically-managed Graves disease visits her endocrinologist to discuss her desire to become pregnant and whether pregnancy is safe with her medications. Her temperature is 98.4°F (36.9°C), blood pressure is 110/66 mmHg, pulse is 78/min, respirations are 12/min. The endocrinologist advises that the patient may pursue pregnancy, but first needs to be switched from methimazole to propylthiouracil for her Graves disease due to pregnancy safety considerations. Which of the following is a possible side effect of propylthiouracil that represents a greater risk compared to methimazole?
Q488
A 52-year-old male with ischemic cardiomyopathy presents to his cardiologist for worsening shortness of breath on exertion. He denies any recent episodes of chest pain and has been compliant with his medications, which include metoprolol, lisinopril, spironolactone, and furosemide. The patient’s vitals signs are as follows: Temperature is 98.7 deg F (37.1 deg C), blood pressure is 163/78 mmHg, pulse is 92/min, respirations are 14/min, and oxygen saturation is 98% on room air. A repeat echocardiogram reveals a stable LVEF of 25-35%. The physician decides to start hydralazine and isosorbide dinitrate. Which of the following is true regarding this medication combination?
Q489
A 52-year-old man presents to the emergency department with nausea, palpitations, and lightheadedness after consuming a drink prepared from the leaves of yellow oleander (Thevetia peruviana). He had read somewhere that such a drink is healthy. As he liked the taste, he consumed 3 glasses of the drink before the symptoms developed. He also vomited twice. There is no past medical history suggestive of any significant medical condition. On physical examination, he is disoriented. The temperature is 36.5°C (97.8°F), the pulse is 140/min and irregular, the blood pressure is 94/58 mm Hg, and the respiratory rate is 14/min. Auscultation of the heart reveals an irregularly irregular heartbeat, while auscultation of the lungs does not reveal any significant abnormalities. The abdomen is soft and the pupillary reflexes are intact. An electrocardiogram shows peaked T waves. A botanist confirms that yellow oleander leaves contain cardiac glycosides. In addition to controlling the airway, breathing, and circulation with supportive therapy, which of the following medications is indicated?
Q490
A group of researchers wish to develop a clinical trial assessing the efficacy of a specific medication on the urinary excretion of amphetamines in intoxicated patients. They recruit 50 patients for the treatment arm and 50 patients for the control arm of the study. Demographics are fairly balanced between the two groups. The primary end points include (1) time to recovery of mental status, (2) baseline heart rate, (3) urinary pH, and (4) specific gravity. Which medication should they use in order to achieve a statistically significant result positively favoring the intervention?
Autonomic/CV Drugs US Medical PG Practice Questions and MCQs
Question 481: A 13-year-old boy with a history of asthma and seasonal allergies is currently using albuterol to manage his asthma symptoms. Recently, his use of albuterol increased from 1–2 days/week to 4 times/week over the past several weeks, though he does not experience his symptoms daily. The vital signs include: temperature 36.7°C (98.0°F), blood pressure 126/74 mm Hg, heart rate 74/min, and respiratory rate 14/min. His physical examination shows clear, bilateral breath sounds and normal heart sounds. What change should be made to his current treatment regimen?
A. Add tiotropium
B. Add formoterol + budesonide twice daily
C. Add montelukast 5 mg daily
D. Add fluticasone daily (Correct Answer)
E. Add salmeterol twice daily
Explanation: ***Add fluticasone daily***
- This patient currently has **mild persistent asthma** based on his increased albuterol use (4 times/week, but not daily). The guideline-recommended step-up for mild persistent asthma is the daily addition of a **low-dose inhaled corticosteroid (ICS)** like fluticasone.
- Adding fluticasone daily addresses the underlying inflammation of asthma, reducing symptoms and the need for frequent albuterol rescue inhaler use.
*Add tiotropium*
- Tiotropium, a **long-acting muscarinic antagonist (LAMA)**, is primarily used for asthma as an add-on therapy for patients whose symptoms are not well-controlled with ICS and long-acting beta-2 agonists (LABAs).
- It is not a first-line agent for initiating controller therapy in mild persistent asthma.
*Add formoterol + budesonide twice daily*
- This combination, a **LABA/ICS**, is indicated for moderate to severe persistent asthma, not mild persistent asthma, or can be used as a reliever in older children/adults with mild asthma (SMART therapy).
- Prescribing it twice daily would be an over-treatment for this patient's current asthma severity.
*Add montelukast 5 mg daily*
- Montelukast, a **leukotriene receptor antagonist**, is an alternative for mild persistent asthma, but **ICS are generally preferred** due to superior efficacy in controlling inflammation.
- While it could be considered, fluticasone (an ICS) is a more effective first-line option for controller therapy in mild persistent asthma.
*Add salmeterol twice daily*
- Salmeterol is a **long-acting beta-2 agonist (LABA)** that should never be used as monotherapy in asthma due to the risk of severe exacerbations and asthma-related death.
- LABAs should always be used in combination with an **inhaled corticosteroid (ICS)**.
Question 482: A 25-year-old woman is brought to the emergency department 12 hours after ingesting 30 tablets of an unknown drug in a suicide attempt. The tablets belonged to her father, who has a chronic heart condition. She has had nausea and vomiting. She also reports blurring and yellowing of her vision. Her temperature is 36.7°C (98°F), pulse is 51/min, and blood pressure is 108/71 mm Hg. Abdominal examination shows diffuse tenderness with no guarding or rebound. Bowel sounds are normal. An ECG shows prolonged PR-intervals and flattened T-waves. Further evaluation is most likely to show which of the following electrolyte abnormalities?
A. Increased serum K+ (Correct Answer)
B. Decreased serum K+
C. Decreased serum Na+
D. Increased serum Na+
E. Increased serum Ca2+
Explanation: ***Increased serum K+***
- The patient presents with classic symptoms of **digoxin toxicity**, including **nausea, vomiting, blurry and yellow vision, bradycardia**, and ECG changes like **prolonged PR interval** and **flattened T-waves**.
- **Digoxin inhibits the Na+/K+-ATPase pump**, leading to an increase in extracellular potassium as potassium cannot enter the cells.
*Decreased serum K+*
- While hypokalemia can exacerbate digoxin toxicity by increasing digoxin binding to the Na+/K+-ATPase, digoxin overdose itself typically causes **hyperkalemia** due to its direct effect on the pump.
- ECG changes like **flattened T-waves** can be seen in hypokalemia, but the overall clinical picture, especially the history of overdose and bradycardia, points more strongly to digoxin toxicity with hyperkalemia.
*Decreased serum Na+*
- **Hyponatremia** is not a characteristic feature of acute digoxin overdose.
- Digoxin primarily affects potassium and calcium channels, with less direct impact on sodium levels, unless related to fluid status changes which are not indicated here.
*Increased serum Na+*
- **Hypernatremia** is not typically associated with digoxin toxicity.
- Digoxin's mechanism of action does not directly lead to increased serum sodium; rather, it primarily inhibits the Na+/K+-ATPase.
*Increased serum Ca2+*
- Digoxin **increases intracellular calcium** by inhibiting the Na+/K+-ATPase, which indirectly leads to increased Na+/Ca2+ exchanger activity.
- However, this primarily affects intracellular levels and **does not typically result in increased serum calcium**.
Question 483: A 52-year-old woman complains of severe vomiting for the past 2 hours. She recently had a chemotherapy session for breast cancer. She denies a history of any relevant gastrointestinal diseases, including GERD. The physical exam does not demonstrate any epigastric or abdominal tenderness. The last bowel movement was yesterday and was normal. What is the primary mechanism of the drug which would be prescribed to treat her chief complaint?
A. 5-HT3 blocker (Correct Answer)
B. 5-HT1 blocker
C. D1 blocker
D. 5-HT2 blocker
E. 5-HT4 blocker
Explanation: ***5-HT3 blocker***
- **Chemotherapy-induced nausea and vomiting (CINV)** is primarily mediated by the release of **serotonin (5-HT)** from enterochromaffin cells in the gastrointestinal tract, which then acts on **5-HT3 receptors**.
- **5-HT3 receptor antagonists** (e.g., ondansetron, granisetron, palonosetron) are highly effective in preventing and treating CINV by blocking these receptors in the gut and the **chemoreceptor trigger zone (CTZ)**.
*5-HT1 blocker*
- **5-HT1 receptors** are generally associated with other functions, such as **vasoconstriction** and **neuronal inhibition**, and are not the primary target for antiemetic therapy in CINV.
- Triptans, for example, are **5-HT1B/1D agonists** used for migraine, not antiemesis.
*D1 blocker*
- **D1 blockers** (dopamine D1 receptor antagonists) are not typically used as antiemetics.
- **D2 receptor antagonists** (e.g., metoclopramide, prochlorperazine) are antiemetics, acting primarily in the CTZ, but **5-HT3 antagonists** are generally preferred for severe CINV due to their superior efficacy and tolerability.
*5-HT2 blocker*
- **5-HT2 receptors** are involved in various physiological processes, including platelet aggregation and smooth muscle contraction, but are not the main target for antiemetic agents in CINV.
- Some atypical antipsychotics have **5-HT2A blocking activity**, but this is not their primary antiemetic mechanism.
*5-HT4 blocker*
- **5-HT4 receptor blockers** are not used as antiemetics for CINV.
- In contrast, **5-HT4 receptor agonists** (e.g., cisapride, prucalopride) are **prokinetic agents** that stimulate gastrointestinal motility, but these are not indicated for acute chemotherapy-induced vomiting.
Question 484: A 55-year-old male is hospitalized for acute heart failure. The patient has a 20-year history of alcoholism and was diagnosed with diabetes mellitus type 2 (DM2) 5 years ago. Physical examination reveals ascites and engorged paraumbilical veins as well as 3+ pitting edema around both ankles. Liver function tests show elevations in gamma glutamyl transferase and aspartate transaminase (AST). Of the following medication, which most likely contributed to this patient's presentation?
A. Glargine
B. Pramlintide
C. Pioglitazone (Correct Answer)
D. Glipizide
E. Metformin
Explanation: ***Pioglitazone***
- **Pioglitazone**, a thiazolidinedione, is known to cause **fluid retention** and can exacerbate or precipitate **congestive heart failure**.
- The patient's presentation with **ascites**, **pitting edema**, and **acute heart failure** is consistent with the adverse effects of this medication, especially in a patient with risk factors like alcoholism.
*Glargine*
- **Glargine** is a **long-acting insulin** analog primarily used to control blood glucose levels in diabetes.
- It does not typically cause **fluid retention** or worsen **heart failure** directly, making it an unlikely contributor to these specific symptoms.
*Pramlintide*
- **Pramlintide** is an **amylin analog** used to improve glycemic control by slowing gastric emptying and suppressing glucagon secretion.
- It is not associated with **fluid retention** or the exacerbation of **heart failure**.
*Glipizide*
- **Glipizide** is a **sulfonylurea** that stimulates insulin release from pancreatic beta cells.
- While it can cause hypoglycemia, it does not typically contribute to **fluid retention** or worsen **heart failure**.
*Metformin*
- **Metformin** is a **biguanide** that reduces hepatic glucose production and increases insulin sensitivity.
- It is generally considered **cardioprotective** and does not cause **fluid retention** or exacerbate **heart failure**.
Question 485: A patient with Graves' disease is treated with thiocyanate (a historical antithyroid agent). Thiocyanate helps reduce thyroid hormone production by:
A. Inhibiting thyroid peroxidase
B. Inhibiting 5'-deiodinase
C. Inhibiting iodide follicular uptake (Correct Answer)
D. Inhibiting beta-adrenergic receptors
E. Inhibiting thyroid deiodinase
Explanation: ***Inhibiting iodide follicular uptake***
- Thiocyanate is a competitive inhibitor of the **sodium-iodide symporter (NIS)** on thyroid follicular cells, blocking the uptake of iodide into the thyroid gland.
- By preventing iodide entry, thiocyanate reduces the raw material needed for thyroid hormone synthesis, thereby mitigating the **hyperthyroidism** seen in Graves' disease.
*Inhibiting thyroid peroxidase*
- This is the mechanism of action for **thionamide drugs** (e.g., methimazole, propylthiouracil), which block the oxidation of iodide and its organification.
- While effective in Graves' disease, thiocyanate does not directly inhibit thyroid peroxidase activity.
*Inhibiting 5'-deiodinase*
- **Propylthiouracil (PTU)**, but not thiocyanate, inhibits the peripheral conversion of T4 to the more active T3 by blocking 5'-deiodinase enzymes.
- This action helps to reduce the overall effect of thyroid hormones in the body.
*Inhibiting beta-adrenergic receptors*
- **Beta-blockers** (e.g., propranolol) are used to manage the symptomatic effects of hyperthyroidism, such as palpitations, tremor, and anxiety.
- They do not affect thyroid hormone synthesis or release, but rather block the peripheral actions of thyroid hormones on adrenergic receptors.
*Inhibiting thyroid deiodinase*
- This option refers to the enzymes responsible for removing iodine from thyroid hormones, which is part of the normal catabolism of these hormones or for converting T4 to T3.
- Thiocyanate does not primarily act by inhibiting these deiodinase enzymes within the thyroid gland or peripherally; its main action is on iodide uptake.
Question 486: A 42-year-old woman, gravida 1, para 0, at 10 weeks' gestation comes to the physician for a prenatal examination. She has no history of significant medical illness. Physical examination shows a uterus consistent with a 10-week gestation. Cell-free fetal DNA testing shows a karyotype of 47,XXY. If the fetus's condition had not been diagnosed until puberty, which of the following sets of hormonal changes would most likely be found at that time?
$$$ Follicle-stimulating hormone %%% Luteinizing hormone %%% Testosterone %%% Estrogen $$$
A. ↑ ↑ ↓ ↑ (Correct Answer)
B. ↓ ↓ normal ↑
C. ↑ ↑ normal normal
D. ↓ ↓ ↓ ↓
E. ↑ ↑ ↑ ↓
Explanation: ***↑ ↑ ↓ ↑***
- This hormonal pattern is characteristic of **Klinefelter syndrome (47,XXY)** at puberty, where testicular dysfunction leads to **primary hypogonadism**.
- **Decreased testosterone** due to impaired Leydig cell function causes **increased LH and FSH** (due to a lack of negative feedback), while aromatization of excess androgens in peripheral tissues results in **increased estrogen**.
*↓ ↓ normal ↑*
- This pattern (low FSH, low LH, normal testosterone, high estrogen) would suggest **secondary hypogonadism** or an estrogen-producing tumor, which is not consistent with Klinefelter syndrome.
- In secondary hypogonadism, the pituitary is the primary problem, leading to insufficient gonadotropin production; however, in Klinefelter, the problem is primarily testicular.
*↑ ↑ normal normal*
- While FSH and LH are elevated in Klinefelter syndrome, testosterone is typically *decreased*, not normal, and estrogen is often *increased*, not normal.
- This option does not fully capture the classic hormonal profile of **primary hypogonadism with feminization** seen in Klinefelter syndrome.
*↓ ↓ ↓ ↓*
- This pattern of universally low hormone levels is not typical for Klinefelter syndrome.
- Such widespread reduction in hormones might be seen in severe **panhypopituitarism**, which affects multiple endocrine axes and is a distinct condition.
*↑ ↑ ↑ ↓*
- While FSH and LH are elevated, and testosterone is decreased, estrogen is typically *increased* (due to peripheral conversion of androgens) in Klinefelter syndrome, not decreased.
- A decrease in estrogen along with elevated gonadotropins and decreased testosterone would indicate a different type of hormonal imbalance, possibly associated with **severe ovarian failure** if it were a female.
Question 487: A 30-year-old woman with a 1-year history of medically-managed Graves disease visits her endocrinologist to discuss her desire to become pregnant and whether pregnancy is safe with her medications. Her temperature is 98.4°F (36.9°C), blood pressure is 110/66 mmHg, pulse is 78/min, respirations are 12/min. The endocrinologist advises that the patient may pursue pregnancy, but first needs to be switched from methimazole to propylthiouracil for her Graves disease due to pregnancy safety considerations. Which of the following is a possible side effect of propylthiouracil that represents a greater risk compared to methimazole?
A. Thyroid storm
B. Agranulocytosis
C. Fulminant hepatic necrosis (Correct Answer)
D. Skin rash
E. Aplastic anemia
Explanation: ***Fulminant hepatic necrosis***
- Propylthiouracil (PTU) carries a **black box warning** for severe liver injury, including **fulminant hepatic necrosis**, which is a greater risk compared to methimazole.
- This risk is particularly relevant in the context of pregnancy, as PTU is often preferred in the first trimester due to lower teratogenic risk, but its hepatotoxicity must be closely monitored.
*Thyroid storm*
- **Thyroid storm** is a life-threatening exacerbation of hyperthyroidism and is not a direct side effect of antithyroid medications like PTU or methimazole.
- It is a complication of inadequately treated or untreated hyperthyroidism.
*Agranulocytosis*
- **Agranulocytosis** is a rare but serious side effect of both propylthiouracil and methimazole.
- While it is a concern, the risk of fulminant hepatic necrosis is specifically highlighted as being higher with PTU.
*Skin rash*
- **Skin rash** is a common and usually mild side effect that can occur with both methimazole and propylthiouracil.
- It is not typically considered a more severe or distinguishing risk for PTU compared to methimazole.
*Aplastic anemia*
- **Aplastic anemia** is an extremely rare but severe side effect that can be associated with antithyroid drugs, including both PTU and methimazole.
- Although serious, the risk of fulminant hepatic necrosis is a more specifically emphasized and distinct concern for PTU.
Question 488: A 52-year-old male with ischemic cardiomyopathy presents to his cardiologist for worsening shortness of breath on exertion. He denies any recent episodes of chest pain and has been compliant with his medications, which include metoprolol, lisinopril, spironolactone, and furosemide. The patient’s vitals signs are as follows: Temperature is 98.7 deg F (37.1 deg C), blood pressure is 163/78 mmHg, pulse is 92/min, respirations are 14/min, and oxygen saturation is 98% on room air. A repeat echocardiogram reveals a stable LVEF of 25-35%. The physician decides to start hydralazine and isosorbide dinitrate. Which of the following is true regarding this medication combination?
A. Has anti-inflammatory properties to reduce the risk of coronary artery thrombosis
B. Improves symptoms but does not have an overall mortality benefit in patients with congestive heart failure
C. Increases the volume of blood that enters the heart to improve ventricular contraction
D. Has positive effects on cardiac remodeling
E. Decreases the volume and work placed on the left ventricle (Correct Answer)
Explanation: ***Decreases the volume and work placed on the left ventricle***
- The combination of **hydralazine** and **isosorbide dinitrate** acts as a **balanced vasodilator**, reducing both preload and afterload.
- **Hydralazine** primarily reduces **afterload** by dilating arterioles, while **isosorbide dinitrate** primarily reduces **preload** by dilating venules, thereby decreasing the volume and work on the left ventricle.
- This hemodynamic benefit reduces myocardial oxygen demand and improves cardiac output in patients with **HFrEF**.
*Has anti-inflammatory properties to reduce the risk of coronary artery thrombosis*
- This medication combination does **not possess anti-inflammatory properties** and is not used to reduce the risk of **coronary artery thrombosis**.
- **Anti-inflammatory drugs** (like NSAIDs) and **antiplatelet agents** (like aspirin) would be used for such purposes, but they have different mechanisms.
*Improves symptoms but does not have an overall mortality benefit in patients with congestive heart failure*
- This statement is incorrect; the combination of **hydralazine and isosorbide dinitrate** has been shown to improve **mortality** in specific populations, particularly **African Americans with heart failure**, as evidenced by the **A-HeFT trial**.
- The combination showed a **43% reduction in mortality** and significant improvement in quality of life in this population.
- Medications that primarily improve symptoms without mortality benefit include **diuretics** in the absence of congestion.
*Increases the volume of blood that enters the heart to improve ventricular contraction*
- This combination aims to **decrease the volume** and pressure within the heart (preload and afterload), not increase it.
- Increasing ventricular filling volume could worsen shortness of breath in patients with **heart failure** by further engorging the heart chambers and increasing pulmonary congestion.
*Has positive effects on cardiac remodeling*
- While this combination does have some favorable effects on cardiac remodeling through **nitric oxide donation** and reduction in ventricular wall stress, these effects are **less prominent** compared to **ACE inhibitors**, **ARBs**, and **beta-blockers**, which are the cornerstone neurohormonal antagonists.
- The primary benefit of hydralazine-isosorbide dinitrate is through **direct hemodynamic effects** (reducing preload and afterload), which indirectly reduce ventricular wall stress.
- The **most accurate** answer focuses on the direct mechanism: decreasing volume and work on the left ventricle.
Question 489: A 52-year-old man presents to the emergency department with nausea, palpitations, and lightheadedness after consuming a drink prepared from the leaves of yellow oleander (Thevetia peruviana). He had read somewhere that such a drink is healthy. As he liked the taste, he consumed 3 glasses of the drink before the symptoms developed. He also vomited twice. There is no past medical history suggestive of any significant medical condition. On physical examination, he is disoriented. The temperature is 36.5°C (97.8°F), the pulse is 140/min and irregular, the blood pressure is 94/58 mm Hg, and the respiratory rate is 14/min. Auscultation of the heart reveals an irregularly irregular heartbeat, while auscultation of the lungs does not reveal any significant abnormalities. The abdomen is soft and the pupillary reflexes are intact. An electrocardiogram shows peaked T waves. A botanist confirms that yellow oleander leaves contain cardiac glycosides. In addition to controlling the airway, breathing, and circulation with supportive therapy, which of the following medications is indicated?
A. Procainamide
B. Digoxin immune Fab (Correct Answer)
C. Atropine
D. Quinidine
E. Propranolol
Explanation: ***Digoxin immune Fab***
- The patient exhibits symptoms of **cardiac glycoside toxicity**, including nausea, palpitations, lightheadedness, hypotension, and an irregularly irregular heartbeat with peaked T waves on ECG. Yellow oleander contains cardiac glycosides, and **Digoxin immune Fab (Digifab)** specifically binds to and inactivates these toxins.
- This medication is crucial for reversing the effects of severe cardiac glycoside poisoning by preventing them from binding to their target receptors, the **Na+/K+-ATPase pumps**, thereby restoring normal cardiac function.
- The peaked T waves indicate **hyperkalemia**, which occurs in cardiac glycoside toxicity due to inhibition of Na+/K+-ATPase pumps, preventing potassium from entering cells.
*Procainamide*
- **Procainamide** is an antiarrhythmic drug used for various reentrant and ectopic arrhythmias, but it is **contraindicated in digoxin toxicity** as it can worsen myocardial depression and AV blocks.
- Its use in the presence of cardiac glycoside-induced bradyarrhythmias or conduction blocks could be detrimental due to its own negative chronotropic and dromotropic effects.
*Atropine*
- **Atropine** is primarily used to treat **bradycardia** and AV blocks by blocking muscarinic receptors.
- While the patient has an irregular pulse, the primary issue is cardiac glycoside intoxication affecting the Na+/K+-ATPase pump, which can cause various arrhythmias, not solely bradycardia, and atropine does not address the underlying toxin.
*Quinidine*
- **Quinidine** is a Class IA antiarrhythmic that inhibits the **Na+/K+-ATPase pump**, similar to cardiac glycosides.
- Its co-administration with cardiac glycosides can significantly **increase digoxin levels** and exacerbate toxicity, making it an inappropriate choice.
*Propranolol*
- **Propranolol** is a **beta-blocker** that slows sinus heart rate and AV nodal conduction.
- While it might control some tachyarrhythmias, it can worsen **bradycardia and hypotension**, which may be present in cardiac glycoside toxicity, and does not address the underlying toxic mechanism.
Question 490: A group of researchers wish to develop a clinical trial assessing the efficacy of a specific medication on the urinary excretion of amphetamines in intoxicated patients. They recruit 50 patients for the treatment arm and 50 patients for the control arm of the study. Demographics are fairly balanced between the two groups. The primary end points include (1) time to recovery of mental status, (2) baseline heart rate, (3) urinary pH, and (4) specific gravity. Which medication should they use in order to achieve a statistically significant result positively favoring the intervention?
A. Potassium citrate
B. Ascorbic acid (Correct Answer)
C. Tap water
D. Sodium bicarbonate
E. Aluminum hydroxide
Explanation: ***Ascorbic acid***
- Urinary excretion of **weak bases** like amphetamines is enhanced in an **acidic urine environment**. Ascorbic acid, or vitamin C, is an acidic substance that, when administered, can significantly **lower urinary pH**.
- By acidifying the urine, ascorbic acid promotes the **ionization of amphetamines** in the renal tubules, making them less lipid-soluble and decreasing their reabsorption, thereby **increasing their urinary excretion**.
*Potassium citrate*
- Potassium citrate is a **urinary alkalinizer**, meaning it would increase the pH of the urine.
- Increasing urinary pH would **decrease the excretion of acidic drugs** and **increase the reabsorption of basic drugs** like amphetamines, which is the opposite of the desired effect.
*Tap water*
- Administering tap water would primarily lead to **diuresis** (increased urine production) but would have a **negligible effect on urinary pH**.
- While increased urine volume can dilute the concentration of amphetamines, it does not significantly alter the **renal clearance rate based on pH**, which is crucial for weak bases.
*Sodium bicarbonate*
- Sodium bicarbonate is a potent **urinary alkalinizer**, used to increase the pH of the urine.
- Just like potassium citrate, a higher urinary pH would **inhibit the excretion of amphetamines** by promoting their non-ionized, lipid-soluble form and increasing their reabsorption.
*Aluminum hydroxide*
- Aluminum hydroxide is primarily an **antacid** and phosphate binder, used for conditions like GERD or hyperphosphatemia; it has **no significant direct effect on urinary pH or amphetamine excretion**.
- Its action is largely confined to the gastrointestinal tract, and it does not get absorbed in a way that would acidify the urine.
